North America Apixaban Prices Movement Q2:
Apixaban Prices in USA:
During the second quarter of 2025, Apixaban price Trend in the USA reached 44,617 USD/MT in June. Prices followed a steady upward trajectory, supported by consistent demand for cardiovascular and stroke prevention medications. Rising API production and regulatory compliance costs contributed to the increase. Although generic alternatives helped limit sharp price spikes, stable domestic consumption and efficient supply chain operations maintained firm pricing throughout the quarter.
Get the Real-Time Prices Analysis: https://www.imarcgroup.com/apixaban-pricing-report/requestsample
Note: The analysis can be tailored to align with the customer's specific needs.
APAC Apixaban Prices Movement Q2:
Apixaban Prices in China:
In the second quarter of 2025, apixaban prices in China stood at 24,295 USD/MT in June, continuing their upward movement from previous quarters. Strong demand from the cardiovascular drug segment and steady API procurement reinforced price firmness. Limited competition among major domestic manufacturers sustained market stability, while rising fermentation input costs added mild upward pressure on production and pricing.
Apixaban Prices in India:
In the second quarter of 2025, apixaban prices in India were recorded at 30,369 USD/MT in June. The market displayed moderate firmness, supported by steady demand from hospitals and specialty clinics treating cardiovascular diseases. Domestic manufacturers, along with Chinese API suppliers, maintained stable supply conditions. Minor currency fluctuations and rising formulation expenses added slight upward pressure to the overall pricing trend.
Apixaban Prices in Korea:
During the second quarter of 2025, apixaban prices in South Korea reached 43,946 USD/MT in June. Prices remained stable to slightly firm amid consistent demand from the country’s robust healthcare system. While the introduction of generics created mild competition, reliance on imported APIs and growing therapeutic applications kept prices steady. Balanced supply and sustained healthcare utilization ensured pricing resilience throughout the quarter.
Regional Analysis: The price analysis can be extended to provide detailed Apixaban price information for the following list of countries.
China, India, Indonesia, Pakistan, Bangladesh, Japan, Philippines, Vietnam, Thailand, South Korea, Malaysia, Nepal, Taiwan, Sri Lanka, Hongkong, Singapore, Australia, and New Zealand, among other Asian countries.
Europe Apixaban Prices Movement Q2:
Apixaban Prices in Germany:
During the second quarter of 2025, apixaban prices in Germany reached 55,269 USD/MT in June, maintaining relative stability. Strong demand within Germany’s advanced healthcare network and restricted patent-controlled supply contributed to price resilience. Elevated API production costs and delays in generic market entries supported firm pricing, while consistent procurement across hospital and retail channels kept market volatility low.
Regional Analysis: The price analysis can be expanded to include detailed Apixaban price data for a wide range of European countries, such as Germany, France, the United Kingdom, Italy, Spain, Russia, Turkey, the Netherlands, Poland, Sweden, Belgium, Austria, Ireland, Switzerland, Norway, Denmark, Romania, Finland, the Czech Republic, Portugal, and Greece, along with other European nations.
Purchase Options: https://www.imarcgroup.com/checkout?id=22910&method=1925
- Biannual Updates: For 2 Deliverables, Billed Annually
- Quarterly Updates: For 4 Deliverables, Billed Annually
- Monthly Updates: For 12 Deliverables, Billed Annually
We Also Provide News and Historical Data of Apixaban
- Historical Data: Comprehensive historical pricing and market trends.
- Quarterly Analysis: Detailed insights into price fluctuations and market dynamics.
- Regional and Global Data: Coverage of key markets and their performance.
- Forecast Comparisons: Historical data paired with future market projections.
- Customizable Reports: Tailored analysis to meet specific business needs.
What is Apixaban?
Apixaban is an oral anticoagulant belonging to the direct factor Xa inhibitor class. It works by selectively inhibiting factor Xa, an important enzyme involved in blood coagulation, thereby reducing thrombin generation and clot formation. Apixaban is widely recognized as an important active pharmaceutical ingredient (API) for cardiovascular and thromboembolic disease management.
The US FDA identifies apixaban as a factor Xa inhibitor anticoagulant indicated for reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. It is also used in approved indications involving venous thromboembolism, including treatment and prevention of deep vein thrombosis and pulmonary embolism.
Latest Apixaban Prices – Q2 2025
During Q2 2025, the Apixaban price in the USA reached USD 44,617/MT in June 2025. IMARC reported that the US market followed a steady upward price trend during the quarter.
Region | Apixaban Price Q2 2025 |
USA | USD 44,617/MT |
The quoted figure represents an API/industrial pricing benchmark, rather than the retail price paid by patients for finished-dose apixaban medicines.
Apixaban Price Trend in Q2 2025
The Apixaban price trend in Q2 2025 was positive in the US market, with prices reaching USD 44,617/MT in June. The upward movement reflected the market dynamics surrounding pharmaceutical-grade API production, availability, procurement requirements, and supply-chain conditions.
Demand for apixaban is closely connected with pharmaceutical manufacturing requirements for anticoagulant products. As healthcare systems continue to require therapies for thromboembolic conditions, manufacturers maintain procurement requirements for high-quality API supplies.
Apixaban Price Index and Supply Analysis
The Apixaban Price Index reflects the balance between pharmaceutical demand, API manufacturing capacity, raw-material availability, regulatory requirements, inventory levels, and international trade.
API production requires consistent quality control, validated manufacturing processes, analytical testing, and compliance with pharmaceutical standards. Consequently, the pricing structure of apixaban differs from that of conventional commodity chemicals.
Supply availability can also be influenced by manufacturing plant utilization, production schedules, quality-control requirements, regulatory inspections, transportation, and inventory policies. These factors can create regional differences in procurement costs and supplier quotations.
Factors Affecting Apixaban Prices
- API Manufacturing Costs
The cost of producing pharmaceutical-grade apixaban is a major determinant of its market value. Manufacturing complexity, processing requirements, labor, energy, and quality-control expenses influence supplier pricing.
- Raw Material Availability
Availability and prices of chemical intermediates and starting materials can affect overall production economics. Any disruption in upstream supply can increase API manufacturing costs.
- Pharmaceutical Demand
Demand from manufacturers of anticoagulant medicines directly influences procurement requirements for apixaban API.
- Regulatory Compliance
Pharmaceutical APIs must meet stringent quality, purity, documentation, and manufacturing requirements. Compliance expenses can contribute to production costs.
- Manufacturing Capacity
Changes in production capacity, plant utilization, maintenance schedules, and new manufacturing facilities can influence market availability.
- Generic Competition
The competitive landscape among API suppliers and finished-dose manufacturers can affect purchasing strategies and pricing pressure.
- Inventory Levels
Low inventories can encourage replenishment and strengthen supplier bargaining power, whereas comfortable stocks may moderate procurement activity.
- Logistics and Freight
International transportation, insurance, customs, warehousing, and supply-chain disruptions can influence delivered API costs.
Apixaban Supply and Demand Dynamics
The apixaban market is primarily driven by demand from the pharmaceutical sector, where the API is incorporated into finished anticoagulant medicines.
Supply is dependent on specialized pharmaceutical manufacturers capable of meeting stringent quality standards. Unlike bulk industrial chemicals, API availability is influenced not only by physical production capacity but also by regulatory approvals, quality testing, manufacturing validation, and consistency requirements.
On the demand side, the increasing clinical use of direct oral anticoagulants supports continued requirements for apixaban across pharmaceutical manufacturing chains. Its approved uses include prevention of stroke and systemic embolism in nonvalvular atrial fibrillation and management of venous thromboembolism.
Latest Apixaban Market News – Q2 2025
During 2025, the regulatory landscape for apixaban continued to evolve. The US FDA's April 2025 approval documentation included a new pediatric indication for treatment of venous thromboembolism, demonstrating the continuing expansion of approved therapeutic applications around apixaban-based treatment.
The broader pharmaceutical market also continued to focus on reliable API sourcing, manufacturing resilience, regulatory compliance, and supply-chain diversification. These factors remain important for procurement teams evaluating apixaban availability and pricing.
Current Apixaban Demand
Current demand for apixaban is primarily generated by pharmaceutical manufacturers producing anticoagulant medicines.
Key demand areas include:
- Nonvalvular atrial fibrillation treatment
- Stroke and systemic embolism prevention
- Deep vein thrombosis treatment
- Pulmonary embolism treatment
- Prevention of recurrent venous thromboembolism
- Post-surgical thrombosis prevention in approved indications
- Pediatric venous thromboembolism treatment under approved indications
The continuing use of direct oral anticoagulants in appropriate patient populations provides an important foundation for apixaban API demand.
Future Apixaban Demand
The future demand outlook for apixaban remains supported by its established role as a direct factor Xa inhibitor and its broad clinical applications.
Demand is expected to remain connected to the prevalence of atrial fibrillation and venous thromboembolic disorders, healthcare access, pharmaceutical production volumes, and the development of generic and other competing products.
Expansion of approved indications, including pediatric applications, can further broaden potential pharmaceutical demand. At the same time, increasing competition among API suppliers and finished-dose manufacturers may influence procurement strategies and pricing.
Previous Year Apixaban Price Comparison
A precise Q2 2024 versus Q2 2025 comparison requires the same IMARC benchmark and pricing methodology for both periods. The currently accessible IMARC result confirms the Q2 2025 US price of USD 44,617/MT, but does not expose a comparable Q2 2024 value in the retrieved material.
Therefore, an exact year-on-year percentage change should not be calculated without the corresponding Q2 2024 benchmark.
Period | USA Apixaban Price |
Q2 2025 | USD 44,617/MT |
This approach ensures that the comparison remains consistent and avoids mixing different API grades, trade bases, or pricing methodologies.
Apixaban Price Outlook 2025
The Apixaban price outlook for 2025 remains dependent on pharmaceutical demand, API production capacity, raw-material costs, regulatory requirements, inventory levels, and supplier competition.
The US market entered the second quarter with an upward price trajectory, reaching USD 44,617/MT in June 2025.
Future prices could remain firm if pharmaceutical procurement expands or API availability becomes constrained. Conversely, additional manufacturing capacity, improved raw-material availability, and stronger supplier competition could moderate price increases
Major Uses of Apixaban
- Stroke and Systemic Embolism Prevention
Apixaban is used to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation under approved indications.
- Deep Vein Thrombosis
It is used in approved treatment and prevention strategies for deep vein thrombosis.
- Pulmonary Embolism
Apixaban is used for the treatment of pulmonary embolism and prevention of recurrent thromboembolic events under approved indications.
- Venous Thromboembolism Prevention
The API is incorporated into medicines used to prevent venous thromboembolic events in appropriate clinical settings.
- Pediatric VTE Applications
US regulatory developments in 2025 expanded approved use to include treatment of venous thromboembolism in pediatric patients meeting the relevant criteria.
Most Asked FAQs About Apixaban
- What is Apixaban?
Apixaban is an oral direct factor Xa inhibitor anticoagulant used to reduce blood-clot formation in several approved cardiovascular and thromboembolic indications.
- What was the Apixaban price in Q2 2025?
The Apixaban price in the USA reached USD 44,617/MT in June 2025, according to the available IMARC pricing benchmark.
- What factors affect Apixaban prices?
API manufacturing costs, raw-material availability, pharmaceutical demand, production capacity, regulatory compliance, inventory levels, supplier competition, and logistics can influence apixaban prices.
- What is Apixaban mainly used for?
Apixaban is primarily used in approved indications for reducing stroke and systemic embolism risk in nonvalvular atrial fibrillation and for treating or preventing venous thromboembolism.
- Is Apixaban an anticoagulant?
Yes. Apixaban is a factor Xa inhibitor anticoagulant.
- What is driving Apixaban demand?
Pharmaceutical demand for anticoagulant medicines, continued clinical use in atrial fibrillation and venous thromboembolism, healthcare requirements, and expansion of approved indications support apixaban demand.
- What is the future price outlook for Apixaban?
The outlook will depend on API availability, pharmaceutical demand, manufacturing capacity, raw-material costs, regulatory conditions, and competitive dynamics among suppliers.
Key Takeaway
The Apixaban market recorded a firm pricing environment during Q2 2025, with the US API benchmark reaching USD 44,617/MT in June. Pharmaceutical demand, manufacturing economics, regulatory requirements, API availability, and supply-chain conditions remain central to pricing. Continued demand for anticoagulant therapies and evolving approved indications provide a supportive foundation for future apixaban consumption.
Note: Apixaban is a prescription anticoagulant. The information above is intended for pharmaceutical market and pricing analysis, not for individual medical treatment or dosing decisions.
Speak to An Analyst: https://www.imarcgroup.com/request?type=report&id=22910&flag=C
Key Coverage:
- Market Analysis
- Market Breakup by Region
- Demand Supply Analysis by Type
- Demand Supply Analysis by Application
- Demand Supply Analysis of Raw Materials
- Price Analysis
- Spot Prices by Major Ports
- Price Breakup
- Price Trends by Region
- Factors influencing the Price Trends
- Market Drivers, Restraints, and Opportunities
- Competitive Landscape
- Recent Developments
- Global Event Analysis
How IMARC Pricing Database Can Help
The latest IMARC Group study, “Apixaban Prices, Trend, Chart, Demand, Market Analysis, News, Historical and Forecast Data 2025 Edition,” presents a detailed analysis of Apixaban price trend, offering key insights into global Apixaban market dynamics. This report includes comprehensive price charts, which trace historical data and highlights major shifts in the market.
The analysis delves into the factors driving these trends, including raw material costs, production fluctuations, and geopolitical influences. Moreover, the report examines Apixaban demand, illustrating how consumer behaviour and industrial needs affect overall market dynamics. By exploring the intricate relationship between supply and demand, the prices report uncovers critical factors influencing current and future prices.
About Us:
IMARC Group is a global management consulting firm that provides a comprehensive suite of services to support market entry and expansion efforts. The company offers detailed market assessments, feasibility studies, regulatory approvals and licensing support, and pricing analysis, including spot pricing and regional price trends. Its expertise spans demand-supply analysis alongside regional insights covering Asia-Pacific, Europe, North America, Latin America, and the Middle East and Africa. IMARC also specializes in competitive landscape evaluations, profiling key market players, and conducting research into market drivers, restraints, and opportunities. IMARC’s data-driven approach helps businesses navigate complex markets with precision and confidence.
Contact us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No: (D) +91 120 433 0800
United States: +1-631-791-1145
Comments